News

Eli Lilly and Co. shares are trading higher on Tuesday as the company is reporting new data on its treatment for ulcerative colitis (UC). Omvoh Shows Durable Disease Clearance Disease clearance was evaluated among patients who achieved clinical remission with Omvoh at one year in the LUCENT-2 maintenance study and continued treatment in LUCENT-3, an open-label extension study. Eli Lilly’s recent data from the LUCENT-3 clinical trial shows that over 63.5% of patients treated with Omvoh (mirikizum

Eli Lilly's strong GLP-1 drug demand and pipeline advances drive growth, while Western Digital and Vertiv ride AI-fueled momentum and market expansion.

(Bloomberg) -- Eli Lilly & Co. sold $9 billion of investment-grade bonds Wednesday — the company’s biggest-ever issuance — as it looks to finance an acquisition spree. Most Read from BloombergUS Has Opened a Passage Through Hormuz, Central Command SaysUS Says Offensive Phase of Iran War Over as Ship Hit in StraitAnthropic Unveils AI Agents to Field Financial Services TasksDOJ Plans Intervention in Trump Supreme Court Carroll AppealTrump Pauses Plan to Guide Ships While Seeking Iran DealThe drugm

Eli Lilly (LLY) stock initially sold off on Monday morning, May 4, after the FDA disclosed a liver failure report tied to the company’s new oral obesity drug Foundayo, but shares recovered as analysts argued the reaction may have been overdone. The episode shifted investor attention toward the ...

LLY has cleared a historically bullish trendline on the charts

Health care stocks were mixed Wednesday afternoon, with the NYSE Health Care Index increasing 0.1% a

Lilly surges after a Q1 beat and higher guidance, as Mounjaro and Zepbound fueled 56% revenue growth.

(Updates with the company's response in the fourth paragraph.) Eli Lilly (LLY) is looking to rais

While Eli Lilly has slightly lagged behind the SPX over the past year, Wall Street analysts maintain a bullish outlook on the stock’s prospects.

The Danish drugmaker is riding a wave of peptide craziness as its weight loss tablet crushes its U.S. debut.

Investors are concerned about where the stock market is headed this year. The ongoing geopolitical tensions, inflation concerns, and economic uncertainties are weighing on the market. If you are worried about a market downturn in the near future, there are stocks that can continue to stand strong. The S&P 500 has gained 5% this year, ... If You Want to Beat the Market, Start With These 3 Stocks

The drugmaker's total Indiana capital commitments since 2020 now exceed $21 billion, with a new genetic medicine facility opening in Lebanon

The true narrative for Pfizer (PFE) is not its recent top line earnings beat but the escalating structural tension between its required research spending and an impending revenue void. First quarter 2026 results showed an adjusted earnings per share of $0.75 on $14.5 billion in revenue. While these numbers exceeded consensus estimates, they mask a deeper profitability issue. The primary insight hiding within the earnings noise is that Pfizer is funding its future growth at the direct expense of

In its latest earnings report, the Danish drugmaker said sales and profit should shrink less than the company originally anticipated thanks to strong prescription numbers for its new obesity pill.

The launch in January came amid a battle in the market with Mounjaro manufacturer Eli Lilly.

Novo Nordisk stock rose as it raised its guidance on the back of the strong performance of its weight-loss pill.

Total prescriptions for the new Wegovy pill reached around 1.3 million in the first quarter and have exceeded 2 million since it launched.

Total prescriptions for the Wegovy pill reached around 1.3 million in the first quarter and have exceeded 2 million since it launched.

COPENHAGEN, May 6 () - Novo Nordisk, the maker of weight-loss drug Wegovy, on Wednesday reported first-quarter revenue and adjusted operating profit above expectations and said its outlook ‌for the year was slightly improved. The Danish drugmaker is banking on demand for ‌its new weight-loss pill as competition with U.

Schrodinger (NASDAQ:SDGR) reported first-quarter 2026 results and highlighted progress in its transition to hosted software licensing, growth in annual contract value (ACV), and recent business development activity tied to its drug discovery collaborations. First-quarter metrics and hosted transiti

Moby summary of Alkermes plc's Q1 2026 earnings call

Lilly's Foundayo is off to a strong start, drawing new prescribers and patients as broad pharmacy access and payer coverage fuel early oral obesity momentum.

Eli Lilly (NYSE:LLY) received another bullish call from Wall Street. Barclays analyst Emily Field raised her price target on Eli Lilly stock to $1,400 from $1,350 and reiterated an Overweight rating, citing tirzepatide momentum that “takes focus back to the big picture.” The firm also lifted its estimates following the company’s Q1 2026 report. For ... Barclays Hikes Eli Lilly Price Target to $1,400: Tirzepatide Momentum Steals the Show

Competition from Eli Lilly puts pressure on margins despite strong early uptake

Novo Nordisk A/S (NYSE:NVO) is experiencing strong early uptake for its new weight-loss pill, but intensifying competition with U. S.

The company still has a strong lead in its core therapeutic area.

Novo Nordisk's oral semaglutide for obesity is gaining traction as demand picks up for the new pill version of Ozempic. The FDA has proposed restricting compounding of GLP-1 drugs such as semaglutide, which could support branded products. Rival Eli Lilly is facing delays to its own obesity pill, giving Novo Nordisk more room to build its lead in oral GLP-1 therapies. Novo Nordisk is responding with new leadership, pricing changes, and cost reductions to sharpen its obesity drug focus. Novo...

Eli Lilly and Company (NYSE:LLY) held its 2026 annual meeting of shareholders virtually, with Vice President of Sustainability Jim Greffet moderating and Chair, President, and CEO Dave Ricks leading the formal business and post-vote remarks. Greffet opened the meeting with standard notices about for

Eli Lilly's valuation looks far more attractive now than it did even a year ago.

These stocks have been struggling over the past year, but their growth days are far from over.